Compare Neurocrine Biosciences Inc (NBIX) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prudential PLC — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Prudential PLC trades at $27.1 (market cap $34.05B). The key difference: Prudential PLC is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Prudential PLC pays a 2.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PUK | |
|---|---|---|
Market Cap | $15.77B | $34.05B |
Sector | Health | Financials |
52-Week High | $185.50 | $33.61 |
52-Week Low | $123.10 | $24.98 |
Enterprise Value | $15.78B | $33.60B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Prudential (PUK) trades at $27.42, down 1.19% with bearish technical signals but strong fundamentals including 14.52% net margin and 19.24% ROE. Recent earnings show mixed results with Q2 2026 missing expectations while maintaining revenue growth to $27.4B in 2025. The company demonstrates improved cash flow generation with $1.93B net cash flow in 2025 and continues shareholder returns through dividends.
The stock presents value with a 9.64 P/E ratio amid analyst optimism (50% buy ratings), though China regulatory risks and technical bearishness warrant caution. Long-term growth prospects in Asian markets and capital return initiatives support investment case, but investors should monitor execution of the five-year strategic reshaping plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
